Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

National Public Reporting Of Health-Care-asociated Infections Supported By Experts
Five organizations representing the nation"s experts in infectious diseases medicine, infection prevention in healthcare settings, and public health and disease prevention announced their support for a provision requiring national reporting of healthcare-associated infection (HAI) rates, which is contained within the healthcare reform bill introduced by leaders of the U.S. House of Representatives.
generic viagra online
The Evolution Of Migraine From Episodic Headache To Chronic Disorder
Patients living with migraine have strong reason for new optimism concerning a positive future. Two review articles and an accompanying editorial, "The Future of Migraine: Beyond Just Another Pill," in the current issue of Mayo Clinic Proceedings, are the basis for an ironic premise.
News of the day
Baltimore Churches Participate In Program Providing HIV Testing To Residents
Eleven Baltimore churches on Tuesday provided HIV testing to local residents as part of a larger effort by the JACQUES Initiative, a program at the University of Maryland School of Medicine"s Institute of Human Virology, the Baltimore Sun reports. The JACQUES Initiative launched Project SHALEM in partnership with the Maryland AIDS Administration and several local faith-based and community organizations, according to the Sun. Derek Spencer, the executive director of the JACQUES Initiative, said, "The ultimate goal is to make churches, mosques and synagogues a safe place where people can receive HIV support. We are no longer going to wait for people to come into our academic centers for help." He said organizers hoped to test 1,000 people, noting that at one of the testing sites, within the first hour, four people tested positive with the rapid oral swab tests. Angela Wakhweya, deputy director of the Maryland AIDS Administration, said the goal of the project is to eliminate new HIV cases in the state (Bass, 7/22).
Endocrinology

PAION AG: Phase Ib And IIa Studies Of The Anesthetic/Sedative CNS 7056 On Track

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that the respective Data Monitoring Committees (DMCs), after predefined interim analyses, recommended that the Company should proceed as planned with their Phase IIa study as well as Phase Ib of CNS 7065, a new short-acting intravenous anesthetic/sedative. Following the successful proof of concept study reported in January 2009, a Phase IIa study (single dose) in patients undergoing endoscopy of the upper gastrointestinal tract and a Phase Ib study (multiple dose) in volunteers undergoing a colonoscopy, were started. The Phase IIa study is designed to evaluate the safety and the success of sedation of CNS 7056, as well as the time to full recovery and discharge, in comparison to the "gold-standard" agent, midazolam. The Phase Ib study will allow PAION to generate additional data on pharmacodynamics and pharmacokinetics. Both studies are aimed to determine dose regimes for the further clinical development. As of today more than 50% of the patients/volunteers, respectively, have been recruited in both trials. On 11 May 2009 positive results of the first part of the Phase Ib trial were reported. The effect of CNS 7056 can be reversed by an established antagonist, flumazenil; no re-sedation of the volunteers was observed. "While we have already demonstrated proof of concept in our earlier Phase I first in man study, we are now looking forward to identify the best dose regimes for the next steps of the clinical program for which we are already initiating preparatory work" commented Dr. Wolfgang Sç¶hngen, PAION"s CEO. The studies are being performed in the US and PAION expects to report results before the end of 2009. About CNS 7056 / REMIMAZOLAM (pINN) CNS 7056 is a new short-acting sedative and general anesthetic that acts on GABAA receptors. The substance was added to PAION"s portfolio by acquiring CeNeS who in turn had acquired the substance from GlaxoSmithKline. CNS 7056 is a water-soluble, rapid and short-acting GABAA receptor modulator interacting with the benzodiazepine site. The clinical proof of concept study, reported in January 2009, showed that, after intravenous administration, CNS 7056 rapidly induces sedation. Importantly the sedative effects rapidly disappear after cessation of administration. The rapid offset of effect of the compound is due to its metabolism by esterase enzymes that are widely distributed throughout the body. Therefore it is anticipated that CNS 7056 can be clinically developed as a sedative agent for day case procedures, the induction and maintenance of anesthesia and ICU sedation. PAION initiated partnering discussions in parallel to the ongoing Phase II in order to accelerate the further development of CNS 7056 for territories outside Japan, where the compound is partnered to Ono Pharmaceuticals. PAION


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009